{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T09:26:55Z","timestamp":1768814815147,"version":"3.49.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.clml.2020.08.031","type":"journal-article","created":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T21:28:51Z","timestamp":1601587731000},"page":"e105-e111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma"],"prefix":"10.1016","volume":"21","author":[{"given":"Samer A.","family":"Al-Hadidi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8911-6541","authenticated-orcid":false,"given":"Hubert H.","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto N.","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hun Ju","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.08.031_bib1","first-page":"116","article-title":"Hodgkin lymphoma: a review and update on recent progress","volume":"68","author":"Shanbhag","year":"2018","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2020.08.031_bib2","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11899-017-0385-y","article-title":"Role of radiation therapy in the treatment of Hodgkin lymphoma","volume":"12","author":"Gonzalez","year":"2017","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.clml.2020.08.031_bib3","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/bjh.15695","article-title":"Novel therapeutic agents for relapsed classical Hodgkin lymphoma","volume":"184","author":"Von Keudell","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.08.031_bib4","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","author":"Ramos","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib5","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.clml.2020.08.031_bib6","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/ni.2035","article-title":"T\u00a0cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clml.2020.08.031_bib7","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood-2017-09-772632","article-title":"Biology of classical Hodgkin lymphoma: implications for prognosis and novel therapies","volume":"131","author":"Mottok","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib8","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib9","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.08.031_bib10","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1200\/JCO.2017.76.0793","article-title":"Nivolumab for relapsed\/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort single-arm phase II CheckMate 205 trial","volume":"36","author":"Armand","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib12","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1182\/blood.2019000324","article-title":"Pembrolizumab in relapsed or refractory Hodgkin lymphoma: two-year follow-up of KEYNOTE-087","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib14","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","article-title":"Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure","volume":"34","author":"Armand","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib15","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13045-016-0363-1","article-title":"High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy","volume":"9","author":"Falchi","year":"2016","journal-title":"J\u00a0Hematol Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib17","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1182\/blood-2019-127280","article-title":"Three-year follow-up of Keynote-087: pembrolizumab monotherapy in relapsed\/refractory classic Hodgkin lymphoma","volume":"134","author":"Zinzani","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib19","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1182\/blood-2019-123163","article-title":"Preliminary results from a phase I trial of pembrolizumab plus vorinostat in patients with relapsed or refractory diffuse large B-cell lymphoma, follicular lymphoma, and Hodgkin lymphoma","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"issue":"15 Suppl","key":"10.1016\/j.clml.2020.08.031_bib20","doi-asserted-by":"crossref","first-page":"e20018","DOI":"10.1200\/JCO.2020.38.15_suppl.e20018","article-title":"Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R\/R) Hodgkin lymphoma (HL)","volume":"38","author":"Sermer","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib21","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40425-018-0361-7","article-title":"Radiation therapy and PD-1\/PD-L1 blockade: the clinical development of an evolving anticancer combination","volume":"6","author":"Gong","year":"2018","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.clml.2020.08.031_bib22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.canrad.2018.12.005","article-title":"Radiotherapy in combination with nivolumab for relapsed\/refractory classical Hodgkin lymphoma: about two cases","author":"de Forceville","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.clml.2020.08.031_bib23","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.canrad.2018.05.002","article-title":"Anti-PD-1 immunotherapy in combination with sequential involved-site radiotherapy in heavily pretreated refractory Hodgkin lymphoma","volume":"23","author":"Qu\u00e9ro","year":"2019","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.clml.2020.08.031_bib24","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2017-10-811224","article-title":"Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma","volume":"131","author":"Herrera","year":"2018","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib25","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1182\/blood-2019-122576","article-title":"Brentuximab vedotin and nivolumab for relapsed or refractory classic Hodgkin lymphoma: long-term follow-up results from the single-arm phase 1\/2 study","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib26","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1182\/blood-2019-123162","article-title":"PET-adapted nivolumab or nivolumab Plus ICE as first salvage therapy in relapsed or refractory Hodgkin lymphoma","volume":"134","author":"Herrera","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib27","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1182\/blood-2019-127575","article-title":"High complete response rate observed with second-line chemo-immunotherapy with pembrolizumab and GVD (gemcitabine, vinorelbine, and liposomal doxorubicin) in relapsed and refractory classical Hodgkin lymphoma","volume":"134","author":"Moskowitz","year":"2019","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib28","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.1182\/blood-2019-123879","article-title":"Safety and toxicity profile of pembrolizumab (PEM) in combination with ICE chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory classical Hodgkin lymphoma: no impairment in stem cell mobilization or engraftment","volume":"134","author":"Bryan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib29","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.19.00315","article-title":"Nivolumab for newly diagnosed advanced-stage classic Hodgkin lymphoma: safety and efficacy in the phase II CheckMate 205 study","volume":"37","author":"Ramchandren","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1182\/blood-2019-123906","article-title":"Brief pembrolizumab (PEM) monotherapy results in complete and near complete responses in the majority of untreated patients with classical Hodgkin lymphoma (cHL): a multicenter phase 2 PET-adapted study of sequential PEM and AVD","volume":"134","author":"Allen","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1001\/jamaoncol.2020.0750","article-title":"Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin study group NIVAHL trial","volume":"6","author":"Br\u00f6ckelmann","year":"2020","journal-title":"JAMA Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.clml.2020.08.031_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/blood-2019-124866","article-title":"Phase 2 study of frontline brentuximab vedotin plus nivolumab in patients with Hodgkin lymphoma aged\u00a0\u226560 years","volume":"134","author":"Yasenchak","year":"2019","journal-title":"Blood"},{"issue":"15 Suppl","key":"10.1016\/j.clml.2020.08.031_bib33","doi-asserted-by":"crossref","first-page":"8014","DOI":"10.1200\/JCO.2020.38.15_suppl.8014","volume":"38","author":"Cheson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib34","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood.2019000215","article-title":"PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem-cell transplantation","volume":"134","author":"Armand","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib36","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.031_bib37","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib38","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.4049\/jimmunol.1400954","article-title":"Programmed death-1 pathway in host tissues ameliorates Th17\/Th1-mediated experimental chronic graft-versus-host disease","volume":"193","author":"Fujiwara","year":"2014","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.08.031_bib39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib40","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/bmt.2016.111","article-title":"Fatal GvHD induced by PD-1 inhibitor pembrolizumab in a patient with Hodgkin\u2019s lymphoma","volume":"51","author":"Singh","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2020.08.031_bib41","doi-asserted-by":"crossref","first-page":"13260","DOI":"10.18632\/oncotarget.7177","article-title":"Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective","volume":"7","author":"Villasboas","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2020.08.031_bib42","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1634\/theoncologist.2018-0538","article-title":"Outcomes and toxicities of programmed death-1 (PD-1) inhibitors in Hodgkin lymphoma patients in the United States: a real-world, multicenter retrospective analysis","volume":"24","author":"Bair","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.08.031_bib44","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class II and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic Hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.08.031_bib45","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2967\/jnumed.119.232827","article-title":"Early 18F-FDG PET\/CT response predicts survival in relapsed\/refractory Hodgkin lymphoma treated with nivolumab","volume":"61","author":"Chen","year":"2020","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.clml.2020.08.031_bib46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.intimp.2018.03.018","article-title":"Pseudoprogression and hyperprogression after checkpoint blockade","volume":"58","author":"Wang","year":"2018","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.clml.2020.08.031_bib47","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","article-title":"Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy","volume":"128","author":"Cheson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib48","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1182\/blood-2017-11-812073","article-title":"Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma","volume":"131","author":"Spina","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.08.031_bib49","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.237719","article-title":"Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study","author":"Camus","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.08.031_bib50","doi-asserted-by":"crossref","first-page":"102731","DOI":"10.1016\/j.ebiom.2020.102731","article-title":"Circulating tumor DNA predicts response in Chinese patients with relapsed or refractory classical Hodgkin lymphoma treated with sintilimab","volume":"54","author":"Shi","year":"2020","journal-title":"EBioMedicine"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305218?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020305218?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:35:57Z","timestamp":1761870957000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020305218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2152265020305218"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.031","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.08.031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}